Guangxi LiuYao Group (603368) Fundamentals 2026 — P/E 8.8x, Revenue Analysis | SniperIQ
Guangxi LiuYao Group (603368) is a CN-listed Healthcare company in Medical - Distribution with a market capitalization of ¥6.1B, trading at ¥15.33 on the SHH. This SniperIQ fundamentals page covers Guangxi LiuYao Group's valuation (P/E 8.8x, P/B 0.7x), profitability (net margin 3.1%), revenue (¥20.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Guangxi LiuYao Group's market cap?
Guangxi LiuYao Group (603368) has a market capitalization of approximately ¥6.1B, trading at ¥15.33 on the SHH. Market cap moves with the live share price.
What is Guangxi LiuYao Group's P/E ratio?
Guangxi LiuYao Group's trailing twelve-month P/E ratio is 8.8x, with a price-to-book (P/B) of 0.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Guangxi LiuYao Group?
Guangxi LiuYao Group runs a net profit margin of 3.1%, a gross margin of 10.9%, and an operating margin of 4.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Guangxi LiuYao Group generate?
Guangxi LiuYao Group reported revenue of ¥20.9B for fiscal year 2025, with net income of ¥709M and earnings per share (EPS) of 1.79. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Guangxi LiuYao Group pay a dividend?
Guangxi LiuYao Group offers a trailing dividend yield of about 4.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Guangxi LiuYao Group financially healthy?
Guangxi LiuYao Group carries a debt-to-equity ratio of 0.50x and a current ratio of 1.60x, with a market beta of 0.35. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Guangxi LiuYao Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Guangxi LiuYao Group (603368) the key facts are: market cap ¥6.1B, P/E 8.8x, revenue ¥20.9B, 52-week range 14.34-20.92. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Guangxi LiuYao Group's full fundamentals live
Get Guangxi LiuYao Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.